Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand

References

• Thailand’s national strategic plan on antimicrobial resistance 2017-2021. Ministry of Public Health Ministry of Agriculture and Cooperatives National Health Commission Office of Thailand National Health Security Office Thai Health Promotion Foundation Systems Research Institute International Health Policy Program Drug System Monitoring and Development Food and Agriculture of the United Nations World Health Organization; 2016.
   Google Scholar
• European Centre for Disease Prevention and Control ECDC/European Medicines Agency. The bacterial challenge: time to react. Stockholm Sweden: ECDC; 2009.
   Google Scholar
• World Health Organization. Step-by-step approach for development and implementation of hospital antibiotic policy and standard treatment guidelines. New Delhi: WHO regional office for South-East Asia; 2011.
   Google Scholar
• Action on antibiotic resistance. ReAct facts; economic aspects of antibiotic resistance 2008 [cited 2013 Apr 13]. Available from: https://www.reactgroup.org/wp-content/uploads/2016/10/economic-aspects-of-antibiotic-resistance.pdf
   Google Scholar
• O’Neill J Antimicrobial resistance: tackling a crisis for the health and wealth of nations 2014 [cited 2018 Feb 12]. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• The World Bank. Drug-resistant infections: a threat to our economic future. Washington DC, USA: the World Bank; 2016.
   Google Scholar
• The European Commission. A European one health action plan against Antimicrobial Resistance (AMR) 2017 [cited 2018 May 9]. Available from: https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf
   Google Scholar
• Phumart P, Phodha T, Thamlikitkul V, et al. Health and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study. J Health Syst Res. 2012;6(3):352–360.
   Google Scholar
• World Health Organization. Antimicrobial resistance: global Report on surveillance, 2014 [cited 2017 Jun 25]. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
   Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Nordberg P, Monnet DL, Cars O Priority medicines for Europe and the World A public health approach to innovation Solna, Sweden: Swedish Strategic Programme for The Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA), 2004 [cited 2013 Apr 11]. Available from: http://www.reactgroup.org/uploads/publications/react-publications/antibacterial-drug-resistance.pdf
   Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079–1081.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. BAD BUGS, NO DRUGS as antibiotic discovery stagnates a public health crisis brews. Resistance on the rise. Virginia, USA: Infectious Diseases Society of America; 2004.
   Google Scholar
• Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36(11):1433–1437.
   PubMed Web of Science ®Google Scholar
• Kraker M, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in europe. PLoS Med. 2011;8(10):1–8.
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Centre. Antibiotic resistance threats in the United States. Georgia, USA: U.S. Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Riewpaiboon A. Measurement of Costs for Health Economic Evaluation. J Med Assoc Thai. 2014;97(Suppl. 5):S17–S26.
   PubMedGoogle Scholar
• Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014;97(Suppl 5):S127–S134.
   PubMedGoogle Scholar
• Ministry of finance. Public health service fee for treatment reimburstment in government hospital. In: editor. the comptroller general’s department. Bangkok, Thailand: Ministry of finance; 2006:3-1 - 3-2.
   Google Scholar
• Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome*. Am J Med. 2000;109:614–620.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Mody SH, Chen J, et al. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. Surg Infect (Larchmt). 2010;11(5):409–417.
   PubMed Web of Science ®Google Scholar
• Collins CD, Schwemm AK. Linezolid versus vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR trial. Value in health. 2015;18(5):614–621.
   PubMed Web of Science ®Google Scholar
• Institute for Digital Research and Education, University of Clarifornia. STATA web books regression with STATA, 2017 [cited 2017 May 11]. Available from: https://stats.idre.ucla.edu/stata/webbooks/reg/
   Google Scholar
• Hill RC, Griffiths WE, Lim GC. Priciple of econometrics. 4th ed. New Jersey, USA: John Wiley & Sons, Inc.; 2011.
   Google Scholar
• Pena C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother. 2012;56(3):1265–1272.
   PubMed Web of Science ®Google Scholar
• Suarez C, Pena C, Gavalda L, et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis. 2010;14(Suppl 3):e73–e78.
   PubMedGoogle Scholar
• World Health Organization. Life expectancy at birth (years), 2000-2015, 2015 [cited 2017 Aug 1]. Available from: http://gamapserver.who.int/gho/interactive_charts/mbd/life_expectancy/atlas.html
   Google Scholar
• National Antimicrobial Resistance Surveillance Center Thailand. Antibiograms, 2017 [cited 2018 Jan 25]. Available from: http://narst.dmsc.moph.go.th/antibiograms.html
   Google Scholar
• World Health Organization. Report on the burden of endemic health care-associated infection worldwide. Geneva: WHO Patient Safety Programme; 2011.
   Google Scholar
• Thamlikitkul V, Rattanaumpawan P, Boonyasiri A, et al. Thailand antimicrobial resistance containment and prevention program. J Glob Antimicrob Resist. 2015;185:1–5.
   Google Scholar
• Mauldin PD, Salgado CD, Hansen IS, et al. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109–115.
   PubMed Web of Science ®Google Scholar
• Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.
   PubMed Web of Science ®Google Scholar
• Lavi O, Gottesman MM, Levy D. The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat. 2012 Feb-Apr;15(1–2):90–97.
   PubMed Web of Science ®Google Scholar
• Evans HL, Lefrak SN, Lyman J, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35(1):89–95.
   PubMed Web of Science ®Google Scholar
• Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2009;30(1):116–123.
   PubMed Web of Science ®Google Scholar
• Ng E, Earnest A, Lye DC, et al. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41:189–193.
   PubMed Web of Science ®Google Scholar
• Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol. 2014;22(2):99–104.
   Google Scholar
• Smith RD, Coast J. The economic burden of antimicrobial resistance: why it is more serious than current studies suggest. London: London School of Hygiene & Tropical Medicine; 2012.
   Google Scholar